Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. (BIXT) is a clinical-stage biotechnology company whose news flow centers on antiviral drug development, oxygen transport therapies, and advances in stroke and Alzheimer’s research. Company press releases describe a pipeline that includes ProLectin-M, PHM23, and BXT-25, along with collaborations and scientific milestones that support these programs.
News updates frequently highlight clinical trial progress for ProLectin-M, an oral galectin antagonist antiviral being developed under an active IND with the FDA. Bioxytran has reported completion of randomized, double-blind, placebo-controlled trials and dose optimization studies, with endpoints focused on viral load reduction, symptom improvement, and safety. Releases also discuss regulatory interactions with agencies such as the FDA and India’s Central Drugs Standard Control Organization for future trial design.
Another recurring theme in Bioxytran’s news is its oxygen therapeutics platform. The company issues updates on BXT-25 and the Universal Oxygen Carrier project, including securing a GMP-quality source of camel hemoglobin through a joint venture with the Heme Foundation. Articles describe how this work ties into research on mitochondrial function, tissue oxygenation, and the use of the MDX Viewer as a real-time diagnostic tool in stroke and neurodegenerative disease studies.
Bioxytran’s news also covers scientific recognition and partnerships, such as the inclusion of its antiviral PHM23 in a University of Georgia grant submission for Bird Flu research, and publications by scientific advisors on oxygen homeostasis and brain models of ischemic stroke. In addition, the company has announced initiation of independent research coverage of its stock, reflecting interest from micro-cap and small-cap equity research specialists.
Investors and observers who follow BIXT news can expect updates on clinical trial milestones, regulatory submissions, scientific publications, collaborations with academic and nonprofit partners, and developments in its galectin-based antiviral and oxygen transport platforms.
Bioxytran (OTCQB: BIXT) announced on October 29, 2025 the completion of a randomized, double-blind, placebo-controlled dose-optimization trial for its oral broad-spectrum antiviral candidate ProLectin-M. The company says prior Phase 2 results showed treated participants reached undetectable PCR viral levels in less than one week. Data from the new trial will be used to inform a phase 3 trial design for CDSCO and will be submitted to the FDA at the agency's request. Bioxytran expects to compile detailed safety and efficacy endpoints for peer-reviewed publication and plans to submit full results in the coming weeks.
Bioxytran (OTCQB: BIXT) announced a significant scientific advancement with the publication of a groundbreaking book by Prof. Avraham Mayevsky on tissue oxygenation and mitochondrial function. The research highlights the limitations of current peripheral oxygen measurements and introduces a paradigm shift towards tissue-specific oxygenation monitoring.
The company's MDX Viewer technology, combined with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment approaches for conditions like stroke and Alzheimer's disease. The technology will serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical conditions.
Bioxytran (OTCQB: BIXT) has announced significant progress in developing ProLectin-M, its broad-spectrum antiviral drug. The company has completed dosing in its dose optimization clinical trial, marking a crucial milestone in the drug's development.
ProLectin-M targets galectin fold on viral spike proteins and has shown impressive clinical results: 100% response rate (negative PCR tests) by day 7 and 88% response rate by day 3 in double-blinded placebo-controlled trials. The drug has demonstrated effectiveness against SARS-CoV-2, influenza, and RSV, with no viral rebounds during the 14-day observation period.
The drug's development, supported by an active FDA IND application, utilizes proprietary linear complex carbohydrate structures designed with nuclear magnetic resonance and AI to neutralize viral infectiousness.
Bioxytran (OTCQB: BIXT) commemorates 50 years of mitochondrial research advancement, highlighting the historical significance of fiber optic-based fluorometry in brain mitochondrial research through a landmark paper by Prof. Avraham Mayevsky of Bar-Ilan University.
The company's lead drug candidate BXT-25 is advancing toward Phase 1 trials, targeting conditions requiring oxygen transport carrier capabilities, including:
- Ischemic stroke
- Heart attack
- Pulmonary embolism
- Chronic kidney disease (CKD)
- Long Covid
The research emphasizes real-time mitochondrial monitoring through the MDX Viewer, an FDA-approved device measuring tissue metabolic score. The company is exploring partnerships to integrate next-generation monitoring technologies for patient selection and vital sign measurements.
Bioxytran (OTCQB: BIXT) has signed a Non-Disclosure Agreement with the University of Georgia to evaluate its galectin antagonists as a potential treatment for bird flu in chickens. The research collaboration will be led by Dr. Daniel Perez, an expert in virology and poultry medicine who serves as CVI Affiliated Faculty and Caswell Eidson Chair in Poultry Medicine at the university.
The company's leading drug candidate, ProLectin-M, is a galectin antagonist designed to fight viral infections by targeting galectins - proteins involved in viral replication, inflammation, and fibrosis. The drug has shown promise in in vitro studies against viruses similar to the bird flu virus, suggesting potential applications in poultry treatment.
Bioxytran (OTCQB: BIXT) has announced a potential breakthrough in treating Bird Flu (H5N1) in egg-laying chickens through a new water-soluble galectin antagonist currently in preclinical trials. The treatment aims to prevent the need for mass culling during outbreaks by blocking viral entry into cells.
The company's approach leverages galectin antagonists that neutralize the virus by blocking viral adhesion, a mechanism previously demonstrated in Phase 2 human clinical trials and in vitro tests. The carbohydrate-based treatment targets viral spike proteins, preventing them from connecting to cells, potentially offering immediate containment of outbreaks.
This development could significantly impact the poultry industry, which currently faces billions in annual losses due to Bird Flu outbreaks and mandatory culling protocols. Bioxytran is actively seeking partnerships with organizations and government agencies to accelerate the treatment's development and deployment.